Interactions between presynaptic Ca 2+ channels, cytoplasmic messengers and proteins of the synaptic vesicle release complex

By Jarvis S.E.   Zamponi G.W.  

Trends in Pharmacological Sciences, Vol. 22, Iss. 10, 2001-10 ,pp. : 519-525

Elsevier

Access to resources Recommend Favorite

Modulating Ca²⁺ release by the IP₃R/Ca²⁺ channel as a potential therapeutic treatment for neurological diseases

By Chan Carmen CM  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 5, 2013-09 ,pp. : 629-636

Future Science

Access to resources Recommend Favorite

Cyclooxygenase-2 in Synaptic Signaling

By  

Current Pharmaceutical Design, Vol. 14, Iss. 14, 2008-05 ,pp. : 1443-1451

Bentham Science Publishers

Access to resources Recommend Favorite

Levetiracetam: the first SV2A ligand for the treatment of epilepsy

By Klitgaard Henrik   Verdru Peter  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 11, 2007-11 ,pp. : 1537-1545

Informa Healthcare

Access to resources Recommend Favorite

The role of P-glycoprotein in determining the oral absorption and clearance of the NK 2 antagonist, UK-224,671

By Beaumont K.   Harper A.   Smith D.A.   Bennett J.  

European Journal of Pharmaceutical Sciences, Vol. 12, Iss. 1, 2000-11 ,pp. : 41-50

Elsevier

Access to resources Recommend Favorite